Jennifer Lynn  Minai-Azary net worth and biography

Jennifer Minai-Azary Biography and Net Worth

Ms. Minai-Azary joined Context in November 2021 as Chief Financial Officer and Treasurer. She brings more than 25 years of finance and accounting experience and has spent the past decade leading finance teams within the life sciences industry. Ms. Minai-Azary also serves on the board of directors of KAHR Medical Ltd., a clinical stage company developing immune recruiting therapies to treat cancer. Prior to joining the Company, Ms. Minai-Azary served as Chief Financial Officer of Millendo Therapeutics, now Tempest Therapeutics, a publicly-traded biopharmaceutical company. She also served as Vice President, Finance, as well as in other finance roles, at Millendo where she was responsible for the financial reporting, accounting, treasury, tax, and risk management functions. While at Millendo, she played a key role in several financing transactions and company mergers. Before that, she served as Director, Technical Accounting at PAREXEL International. Ms. Minai-Azary began her career at Ernst & Young and held positions of increasing responsibility where she managed financial statement audits for publicly-traded and privately-held clients within a variety of industries.

Ms. Minai-Azary holds a Master of Accounting and a B.B.A. from the University of Michigan.

What is Jennifer Lynn Minai-Azary's net worth?

The estimated net worth of Jennifer Lynn Minai-Azary is at least $26.08 thousand as of June 6th, 2025. Minai-Azary owns 80,010 shares of Context Therapeutics stock worth more than $26,083 as of September 29th. This net worth approximation does not reflect any other investments that Minai-Azary may own. Learn More about Jennifer Lynn Minai-Azary's net worth.

How do I contact Jennifer Lynn Minai-Azary?

The corporate mailing address for Minai-Azary and other Context Therapeutics executives is 2001 Market Street, Suite 3915 Unit #15, Philadelphia, PA, 19103. Context Therapeutics can also be reached via phone at 267-225-7416 and via email at [email protected]. Learn More on Jennifer Lynn Minai-Azary's contact information.

Has Jennifer Lynn Minai-Azary been buying or selling shares of Context Therapeutics?

Jennifer Lynn Minai-Azary has not been actively trading shares of Context Therapeutics in the last ninety days. Most recently, on Friday, June 6th, Jennifer Lynn Minai-Azary bought 40,010 shares of Context Therapeutics stock. The stock was acquired at an average cost of $0.64 per share, with a total value of $25,606.40. Following the completion of the transaction, the chief financial officer now directly owns 80,010 shares of the company's stock, valued at $51,206.40. Learn More on Jennifer Lynn Minai-Azary's trading history.

Who are Context Therapeutics' active insiders?

Context Therapeutics' insider roster includes Martin Lehr (CEO), Alex Levit (Insider), and Jennifer Minai-Azary (CFO). Learn More on Context Therapeutics' active insiders.

Jennifer Lynn Minai-Azary Insider Trading History at Context Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/6/2025Buy40,010$0.64$25,606.4080,010View SEC Filing Icon  
12/16/2022Buy25,000$0.74$18,500.0040,000View SEC Filing Icon  
See Full Table

Jennifer Lynn Minai-Azary Buying and Selling Activity at Context Therapeutics

This chart shows Jennifer Lynn Minai-Azary's buying and selling at Context Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Context Therapeutics Company Overview

Context Therapeutics logo
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Read More

Today's Range

Now: $0.33
Low: $0.32
High: $0.33

50 Day Range

MA: $0.46
Low: $0.33
High: $0.69

2 Week Range

Now: $0.33
Low: $0.32
High: $3.62

Volume

242,182 shs

Average Volume

1,801,877 shs

Market Capitalization

$29.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69